PURPOSE OF REVIEW: Considerable HIV-1 vaccine development efforts have been deployed over the past decade. Put into perspective, the results from efficacy trials and the identification of correlates of risk have opened large and unforeseen avenues for vaccine development. RECENT FINDINGS: The Thai efficacy trial, RV144, provided the first evidence that HIV-1 vaccine protection against HIV-1 acquisition could be achieved. The correlate of risk analysis showed that IgG antibodies against the gp120 V2 loop inversely correlated with a decreased risk of infection, whereas Env-specific IgA directly correlated with risk. Further clinical trials will focus on testing new envelope subunit proteins formulated with adjuvants capable of inducing higher and more durable functional antibody responses (both binding and broadly neutralizing antibodies). Moreover, vector-based vaccine regimens that can induce cell-mediated immune responses in addition to humoral responses remain a priority. SUMMARY: Future efficacy trials will focus on prevention of HIV-1 transmission in heterosexual population in Africa and MSM in Asia. The recent successes leading to novel directions in HIV-1 vaccine development are a result of collaboration and commitment among vaccine manufacturers, funders, scientists and civil society stakeholders. Sustained and broad collaborative efforts are required to advance new vaccine strategies for higher levels of efficacy.
PURPOSE OF REVIEW: Considerable HIV-1 vaccine development efforts have been deployed over the past decade. Put into perspective, the results from efficacy trials and the identification of correlates of risk have opened large and unforeseen avenues for vaccine development. RECENT FINDINGS: The Thai efficacy trial, RV144, provided the first evidence that HIV-1 vaccine protection against HIV-1 acquisition could be achieved. The correlate of risk analysis showed that IgG antibodies against the gp120 V2 loop inversely correlated with a decreased risk of infection, whereas Env-specific IgA directly correlated with risk. Further clinical trials will focus on testing new envelope subunit proteins formulated with adjuvants capable of inducing higher and more durable functional antibody responses (both binding and broadly neutralizing antibodies). Moreover, vector-based vaccine regimens that can induce cell-mediated immune responses in addition to humoral responses remain a priority. SUMMARY: Future efficacy trials will focus on prevention of HIV-1 transmission in heterosexual population in Africa and MSM in Asia. The recent successes leading to novel directions in HIV-1 vaccine development are a result of collaboration and commitment among vaccine manufacturers, funders, scientists and civil society stakeholders. Sustained and broad collaborative efforts are required to advance new vaccine strategies for higher levels of efficacy.
Authors: Stephen R Walsh; Michael S Seaman; Lauren E Grandpre; Cherie Charbonneau; Katherine E Yanosick; Barbara Metch; Michael C Keefer; Raphael Dolin; Lindsey R Baden Journal: Vaccine Date: 2012-11-07 Impact factor: 3.641
Authors: Peter B Gilbert; Marta L Ackers; Phillip W Berman; Donald P Francis; Vladimir Popovic; Dale J Hu; William L Heyward; Faruk Sinangil; Bryan E Shepherd; Marc Gurwith Journal: J Infect Dis Date: 2005-08-12 Impact factor: 5.226
Authors: Eduard J Sanders; Haile S Okuku; Adrian D Smith; Mary Mwangome; Elizabeth Wahome; Gregory Fegan; Norbert Peshu; Elisabeth M van der Elst; Matthew A Price; R Scott McClelland; Susan M Graham Journal: AIDS Date: 2013-01-28 Impact factor: 4.177
Authors: Beryl A Koblin; Martin Casapia; Cecilia Morgan; Li Qin; Zhixue Maggie Wang; Olivier D Defawe; Lindsey Baden; Paul Goepfert; Georgia D Tomaras; David C Montefiori; M Juliana McElrath; Lilian Saavedra; Chuen-Yen Lau; Barney S Graham Journal: PLoS One Date: 2011-09-12 Impact factor: 3.240
Authors: Gerald R Nakamura; Dora P A J Fonseca; Sara M O'Rourke; Aaron L Vollrath; Phillip W Berman Journal: PLoS One Date: 2012-06-13 Impact factor: 3.240
Authors: A Guimarães-Walker; N Mackie; S McCormack; T Hanke; C Schmidt; J Gilmour; B Barin; A McMichael; J Weber; K Legg; A Babiker; P Hayes; F Gotch; C Smith; L Dally; L Dorrell; I Cebere; R Kay; N Winstone; S Moore; N Goonetilleke; P Fast Journal: Vaccine Date: 2008-12-02 Impact factor: 3.641
Authors: Sudhir Pai Kasturi; Pamela A Kozlowski; Helder I Nakaya; Matheus C Burger; Pedro Russo; Mathew Pham; Yevgeniy Kovalenkov; Eduardo L V Silveira; Colin Havenar-Daughton; Samantha L Burton; Katie M Kilgore; Mathew J Johnson; Rafiq Nabi; Traci Legere; Zarpheen Jinnah Sher; Xuemin Chen; Rama R Amara; Eric Hunter; Steven E Bosinger; Paul Spearman; Shane Crotty; Francois Villinger; Cynthia A Derdeyn; Jens Wrammert; Bali Pulendran Journal: J Virol Date: 2017-01-31 Impact factor: 5.103
Authors: Diego A Vargas-Inchaustegui; Iskra Tuero; Venkatramanan Mohanram; Thomas Musich; Poonam Pegu; Antonio Valentin; Yongjun Sui; Margherita Rosati; Jenifer Bear; David J Venzon; Viraj Kulkarni; Candido Alicea; Guy R Pilkington; Namal P M Liyanage; Thorsten Demberg; Shari N Gordon; Yichuan Wang; Alison E Hogg; Blake Frey; L Jean Patterson; Janet DiPasquale; David C Montefiori; Niranjan Y Sardesai; Steven G Reed; Jay A Berzofsky; Genoveffa Franchini; Barbara K Felber; George N Pavlakis; Marjorie Robert-Guroff Journal: Clin Immunol Date: 2014-06-04 Impact factor: 3.969
Authors: Juan García-Arriaza; Beatriz Perdiguero; Jonathan L Heeney; Michael S Seaman; David C Montefiori; Nicole L Yates; Georgia D Tomaras; Guido Ferrari; Kathryn E Foulds; Mario Roederer; Steven G Self; Bhavesh Borate; Raphael Gottardo; Sanjay Phogat; Jim Tartaglia; Susan W Barnett; Brian Burke; Anthony D Cristillo; Deborah E Weiss; Carter Lee; Karen V Kibler; Bertram L Jacobs; Ralf Wagner; Song Ding; Giuseppe Pantaleo; Mariano Esteban Journal: J Virol Date: 2017-04-13 Impact factor: 5.103
Authors: Javier F Morales; Trevor J Morin; Bin Yu; Gwen P Tatsuno; Sara M O'Rourke; Richard Theolis; Kathryn A Mesa; Phillip W Berman Journal: J Biol Chem Date: 2014-07-25 Impact factor: 5.157
Authors: Steven G Reed; Darrick Carter; Corey Casper; Malcolm S Duthie; Christopher B Fox Journal: Semin Immunol Date: 2018-10-23 Impact factor: 11.130